TRPV2 and melanoma: Using combined immunohistochemical and tissue microarray (TMA) analyses (Fig 7B–D and Appendix Fig S10A–D), we assessed TRPV2 expression in situ over 100 patient samples, including 62 malignant melanomas (Grade I‐IV), 20 lymph node metastases and 18 benign nevi.